iPad Technology for HOME Rehabilitation in Patients After Stroke: iHOME Acute/Chronic
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01836159|
Recruitment Status : Completed
First Posted : April 19, 2013
Last Update Posted : October 1, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
A pilot randomized, two parallel group study comparing an iPad software game application versus standard care in post-stroke patients.
Study hypothesis: Tablet PC technology using the iPad is a feasible and potentially efficacious tool which has the potential to promote fine motor recovery of the upper extremity after stroke.
|Condition or disease||Intervention/treatment||Phase|
|Fine Motor Function Deficit and Visual Neglect Post-stroke||Other: iPad Intervention Other: Standard/ Usual Care||Not Applicable|
The standard one hour of out-patient rehabilitation is insufficient in providing the repetitive intense training required for rehabilitation of fine motor recovery. There are also limited interventions are available for home use after discharge from a rehabilitation centre. Hence, there is now a need to determine the feasibility of innovative strategies for home use, to cover the gap after discharge from rehabilitation institutions.
iHOME is an original, low cost, potentially high impact intervention to fulfil this gap. If proven to be effective, the use of tablet technology has a broad range of potential outcomes and benefits. The anticipated public benefit is for stroke patients to be able to potentially employ the iPad, an accessible technological device, as an expansion of rehabilitation in an in-home setting.
iHOME is a pilot randomized controlled trial with a blinded outcome assessment. The trial is subdivided into iHOME Acute and iHOME Chronic, where patients have had a stroke less than 3 months or more than 6 months ago, respectively, at the time of randomization. Participants will be randomly allocated in a 1:1 ratio to the interventions arms (i.e. the investigational and control group).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||29 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||iPad Technology for HOME Rehabilitation in Patients After Stroke: iHOME Acute/Chronic|
|Actual Study Start Date :||June 2014|
|Actual Primary Completion Date :||March 2017|
|Actual Study Completion Date :||March 2018|
Standard/ Usual Care
Patients may receive outpatient rehabilitation as required as part of usual/standard care. No experimental intervention will be given to this group.
Other: Standard/ Usual Care
Patients may receive outpatient rehabilitation as required as part of usual care. Patients will be instructed not to play with an iPad during the 2 week intervention period (in case they have one).
Experimental: iPad Intervention
Patients randomized to the iPad arm will be instructed to self-administer 20 minutes of game sessions per day for 10 days over a 2 week (14 day) period.
Other: iPad Intervention
Patients are to self-administer 20 minutes of gaming sessions, in any configuration that is preferred. Patients will be instructed to play the iPad game with the more affected arm/hand. Start and stop times of the iPad intervention will be downloaded from the iPad, which will allow calculation of the total "dose" received. Patients may receive outpatient rehabilitation as required as part of usual care.
The 'Stroke Rehab' software for the iPad was specifically designed for patients with either fine motor weakness and/or neglect. It contains 6 stages:
- Total "dose" of intervention received as a proportion of the scheduled time [ Time Frame: 10 days over a 2 week period ]The maximum total dose of intervention is 200min (20 min/day x 10 days). A 70% received intervention (≥140 min) from the total scheduled time will be considered successful. This will be measured by the amount of time the patient uses the application (this data is stored in the application).
- Efficacy in fine motor function skills [ Time Frame: 3 business days after final study intervention session ]Efficacy will be measured by an improvement in the time to complete the nine-hole-peg test; the time to magnify and pop the balloons in the iPad software application as determined by the iPad score; the number of fine motor tasks that participants completed on the Wolf Motor Function Test; and an improvement on the Box and Block Test in the post-intervention visit. Efficacy in visual neglect will be measured by an improvement in the Star Cancellation or Line Bisection Test.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 85 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patient has provided written consent prior to entry into the study
- Males or females, 18 - 85 years of age
- Evidence of ischemic or hemorrhagic stroke confirmed by CT or MRI head scan
- Patient with onset of symptoms less than 3 months (for iHOME Acute) or patient more than 6 months (for iHOME Chronic) at the time of randomization
- Measurable deficit of the upper extremity ≥3 according to the Chedoke McMaster scale e.g. participants should be able to touch their chin and contralateral knee to be eligible (for iHome Acute), or measurable deficit of the upper extremity ≥4 according to the Chedoke McMaster scale e.g. participants should be able to touch their chin and contralateral knee to be eligible (for iHome Chronic)
- Functional independence prior to present stroke (mRS = 0-1)
- Patient is alert, medically stable according to the treating physician and able to follow simple verbal commands
- Patient had stroke onset more than 3 months ago (for iHOME Acute) or patient had stroke onset less than 6 months ago (for iHOME Chronic)
- Inability to follow verbal commands or having global aphasia
- Severe illness with life expectancy less than 3 months
- Uncontrolled hypertension, unstable angina, or recent myocardial infarction
- History of seizures
- Participation in another clinical trial involving rehabilitation or investigational drug
- Unable to comply with the protocol
- Patient has any condition(s) that would warrant exclusion from the study
- Any medical condition that might confound the interpretation of results or put the patient at risk
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01836159
|Sunnybrook Health Sciences Centre|
|Toronto, Ontario, Canada, M4N 3M5|
|St. Michael's Hospital|
|Toronto, Ontario, Canada, M5B 1W8|
|Toronto Rehabilitation Institute|
|Toronto, Ontario, Canada, M5G 2A2|
|Study Director:||Tom Schweizer, PhD||Li Ka Shing, St Michael's Hospital|
|Study Director:||Chi-Ming Chow, MD||Unity Health Toronto|
|Principal Investigator:||Gustavo Saposnik, MD, MSc||Unity Health Toronto|
|Responsible Party:||Unity Health Toronto|
|Other Study ID Numbers:||
|First Posted:||April 19, 2013 Key Record Dates|
|Last Update Posted:||October 1, 2019|
|Last Verified:||September 2019|
Fine Motor Function
Central Nervous System Diseases
Nervous System Diseases